← Leaderboards
Anna Palmer Durbin
University Of Vermont & St Agric College
$4,278,996
Attributed
$5,150,253
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.3M · FY2022–25$5M$3.8M$2.5M$1.3M$0
'22
'23
'24
'25
Funding mix
By agency
NIH$5,150,253 · 3
By mechanism
N01$3,418,636 · 1
U01$1,306,885 · 1
P30$424,732 · 1
Top collaborators
- Sean A Diehl2 shared
- Beth Diane Kirkpatrick2 shared
Most similar at University Of Vermont & St Agric College
Same institution · by research overlap
- Beth Diane Kirkpatrick$19,353,029
- Sean A Diehl$2,286,293
- Benjamin Lee$2,697,392
- Jessica W. Crothers$1,258,359
Others in their field
Other Rising Stars on “Adult”
- Jennifer Lee O'Brien · University Of South Florida$15,110,862
- Daniel Hunter Reirden · Westat, Inc.$15,038,020
- Daofeng Li · Salk Institute For Biological Studies$9,887,266
- Gregory Sorenson · University Of Maryland Baltimore County$9,161,697
- April Carson · University Of Mississippi Med Ctr$9,022,104
- Christine W Hockett · Avera Mckennan$8,908,366
Research focus
AdultClinical ResearchPersonsAreaResearch PersonnelVaccinesImmune ResponseInfectionVaccinationUnited States National Institutes Of HealthVaccine CandidateGrowthCohortInnovationClinical TrialsDengue VaccineImmunogenicityDengueInterdisciplinary StudyApplications GrantsImmunotherapeutic AgentInterestChildhoodFaculty
Grant awards (8)
Mechanisms of Protection and Durability for a Live Attenuated Tetravalent Dengue Vaccine$670,995
U01 · FY2025 · AI
Vaccine Response and Immunotherapeutics SWG$65,409
P30 · FY2025 · AI · contact PI
Mechanisms of Protection and Durability for a Live Attenuated Tetravalent Dengue Vaccine$635,890
U01 · FY2024 · AI
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, DOSE-RANGING STUDY TO COMPARE THE SAFETY AND EFFICACY OF 3 DOSE LEVELS OF AV-1 IN HEALTHY ADULTS CHALLENGED WITH A CONTROLLED HUMAN INFECTION S$321,765
N01 · FY2024 · AI · contact PI
Vaccine Response and Immunotherapeutics SWG$58,251
P30 · FY2024 · AI · contact PI
A STUDY TO ASSESS EFFICACY, SAFTETY AND PHARMACOKINETICS OF EYU688 IN HEALTHY PARTICIPANTS CHALLENGED WITH DENGUE SEROTYPE 2$3,096,871
N01 · FY2023 · AI · contact PI
Vaccine Response and Immunotherapeutics SWG$240,263
P30 · FY2023 · AI · contact PI
Vaccine Response and Immunotherapeutics SWG$60,809
P30 · FY2022 · AI · contact PI